Lixte Biotechnology Valuation
| LIXT Stock | USD 1.30 0.10 7.14% |
Today, the firm appears to be overvalued. Lixte Biotechnology secures a last-minute Real Value of $1.25 per share. The latest price of the firm is $1.3. Our model forecasts the value of Lixte Biotechnology from analyzing the firm fundamentals such as Shares Owned By Insiders of 18.71 %, return on equity of -1.27, and Current Valuation of 5.35 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lixte Biotechnology's valuation include:
Overvalued
Today
Please note that Lixte Biotechnology's price fluctuation is abnormally volatile at this time. Calculation of the real value of Lixte Biotechnology is based on 3 months time horizon. Increasing Lixte Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Lixte Biotechnology's intrinsic value may or may not be the same as its current market price of 1.30, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.3 | Real 1.25 | Hype 1.07 | Naive 1.45 |
The intrinsic value of Lixte Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lixte Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lixte Biotechnology Holdings helps investors to forecast how Lixte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lixte Biotechnology more accurately as focusing exclusively on Lixte Biotechnology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lixte Biotechnology's intrinsic value based on its ongoing forecasts of Lixte Biotechnology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lixte Biotechnology's closest peers.
Lixte Biotechnology Cash |
|
Lixte Valuation Trend
Lixte Biotechnology's real value is important for investors to make better decisions and a more accurate overall view of Lixte Biotechnology's financial worth over time. Using both Lixte Biotechnology's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Lixte Biotechnology Total Value Analysis
Lixte Biotechnology Holdings is now anticipated to have valuation of 5.35 M with market capitalization of 3.49 M, debt of 313.86 K, and cash on hands of 7.74 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lixte Biotechnology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.35 M | 3.49 M | 313.86 K | 7.74 M |
Lixte Biotechnology Asset Utilization
One of the ways to look at asset utilization of Lixte is to check how much profit was generated for every dollar of assets it reports. Lixte Biotechnology Holdings secures a negative usage of assets of -0.72 %, losing $0.007188 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Lixte Biotechnology Holdings shows how discouraging it operates for each dollar spent on its assets.Lixte Biotechnology Ownership Allocation
Lixte Biotechnology Holdings secures 18.71 % of its outstanding shares held by insiders and 15.75 % owned by institutional investors.Lixte Biotechnology Profitability Analysis
Net Loss for the year was (5.09 M) with profit before overhead, payroll, taxes, and interest of 0.About Lixte Biotechnology Valuation
The stock valuation mechanism determines Lixte Biotechnology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Lixte Biotechnology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lixte Biotechnology. We calculate exposure to Lixte Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lixte Biotechnology's related companies.| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (12.83) | (13.48) | |
| Operating Profit Margin | (11.91) | (12.50) | |
| Net Loss | (12.83) | (13.48) |
Lixte Biotechnology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Lixte Biotechnology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.9 M |
Lixte Biotechnology Current Valuation Indicators
Lixte Biotechnology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Lixte Biotechnology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lixte Biotechnology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lixte Biotechnology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lixte Biotechnology's worth.Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.